Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy

Clin Lung Cancer. 2024 Dec 13:S1525-7304(24)00263-8. doi: 10.1016/j.cllc.2024.11.014. Online ahead of print.

Authors

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
² Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.. Electronic address: Charu.Aggarwal@pennmedicine.upenn.edu.

PMID: 39743378
DOI: 10.1016/j.cllc.2024.11.014

No abstract available

Keywords: Drug resistance; EGFR mutation; MET mutation; Non-small cell Lung cancer; Tyrosine kinase inhibitor.

Publication types

Case Reports